BACKGROUND: Ampyra was approved to improve walking in patients with MS. Seizures are a known side effect of Ampyra, and seizure risk increases with higher blood levels of the drug. Ampyra is eliminated from the body through the kidneys, and patients with kidney impairment may develop higher blood levels of the drug, thereby increasing their seizure risk.

via Safety Alerts for Human Medical Products > Ampyra dalfampridine: Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients.